Last reviewed · How we verify
NCT00851864
Weight-Adjusted Dosing of Tinzaparin in Pregnancy
Phase 4 trial testing Tinzaparin in Venous Thromboembolism in 13 participants. Completed in 1 May 2011.
1 October 2010
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Enrollment | 13 |
| Start date | 1 October 2007 |
| Primary completion | 1 October 2010 |
| Estimated completion | 1 May 2011 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Tinzaparin — full drug profile →
Conditions studied
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
Sponsor
University of Calgary
Who can join
Adults 18 to 45, female only, with Venous Thromboembolism. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Rate of anti-Xa levels falling outside the target range of 0.4-1.2IU/mL
Time frame: anti-Xa level Day 1,28, then q4 weeks
Sponsor's own description
The purpose of this study is to evaluate the safety and efficacy of therapeutic anticoagulation with tinzaparin during pregnancy via weight-based dosing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00851864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tinzaparin
Trials testing the same drug.
- NCT05625932 — TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer · Phase 3 · completed
- NCT07361679 — LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention · Phase 4 · recruiting
- NCT04730856 — Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 P · NA · completed
- NCT03240120 — A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism · Phase 3 · unknown
- NCT02719418 — Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses · completed
Other recruiting trials for Venous Thromboembolism
Currently open trials in the same condition.
- NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
- NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
- NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00851864 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 14 August 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00851864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing